Recent therapeutic advances, especially the development of V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF), mitogen-activated extracellular signal-regulated kinase (MEK) and immune check-point inhibitors, have improved the outlook of patients with stage III and IV melanoma significantly even though many patients still die of their disease [1]. The gene discussed is BRAF; the disease is melanoma.